Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 7, Pages 984
Publisher
MDPI AG
Online
2019-07-15
DOI
10.3390/cancers11070984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
- (2019) Ghaneya Al-Khadairi et al. Journal of Translational Medicine
- Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma
- (2018) Domenico Orlando et al. CANCER RESEARCH
- Current status and future directions of cancer immunotherapy
- (2018) Hongming Zhang et al. Journal of Cancer
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
- (2018) Sietse J Luk et al. OncoImmunology
- Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
- (2017) Kunio Iura et al. HUMAN PATHOLOGY
- A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
- (2017) Aaron Y. Chang et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes
- (2017) M D Mathias et al. LEUKEMIA
- PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy
- (2017) Yan-Huan Zhang et al. LEUKEMIA RESEARCH
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
- (2017) Dmitry Pankov et al. Oncotarget
- PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
- (2017) Gülçin Gezgin et al. JAMA Ophthalmology
- PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
- (2016) M. G. Field et al. CLINICAL CANCER RESEARCH
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
- (2016) Jean-Louis Pujol et al. Journal of Thoracic Oncology
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
- (2015) Catherine Gérard et al. JOURNAL OF IMMUNOTHERAPY
- Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
- (2015) Lotte Spel et al. Oncotarget
- Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials
- (2014) Zhong-chuan Lv et al. TUMOR BIOLOGY
- PRAME Gene Expression in Childhood Acute Lymphoblastic Leukemia: Impact on Prognosis
- (2013) Ca Abdelmalak et al. Clinical Laboratory
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and Is Upregulated by Interferon-Gamma and Bacterial PAMPs
- (2013) Frances R. Wadelin et al. PLoS One
- Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
- (2013) Yushi Yao et al. PLoS One
- Tumor Subtype-Specific Cancer-Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
- (2013) J. Yao et al. Cancer Immunology Research
- Expression and prognostic relevance of PRAME in primary osteosarcoma
- (2012) Pingxian Tan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- All-transretinoic acid in the treatment of pediatric acute promyelocytic leukemia
- (2012) Riccardo Masetti et al. Expert Review of Anticancer Therapy
- PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions
- (2012) Miroslaw J. Szczepanski et al. ORAL ONCOLOGY
- The Human EKC/KEOPS Complex Is Recruited to Cullin2 Ubiquitin Ligases by the Human Tumour Antigen PRAME
- (2012) Adalberto Costessi et al. PLoS One
- High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
- (2011) C. Quintarelli et al. BLOOD
- Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine
- (2011) Mengyong Yan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer
- (2011) A. L. Amir et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters
- (2011) Adalberto Costessi et al. EMBO JOURNAL
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
- (2011) Elisabetta Fratta et al. Molecular Oncology
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of chronic myeloid leukemia stem cells
- (2010) Jonathan M. Gerber et al. AMERICAN JOURNAL OF HEMATOLOGY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia
- (2010) Tim Luetkens et al. LEUKEMIA RESEARCH
- Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia
- (2010) Frances Wadelin et al. Molecular Cancer
- The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells
- (2009) V. G. Oehler et al. BLOOD
- Identification of genes associated with non-small-cell lung cancer promotion and progression
- (2009) Jasna Bankovic et al. LUNG CANCER
- Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia
- (2008) Christina A. Ortmann et al. ANNALS OF HEMATOLOGY
- PRAME expression and clinical outcome of breast cancer
- (2008) M T Epping et al. BRITISH JOURNAL OF CANCER
- Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer
- (2008) A. Woloszynska-Read et al. CLINICAL CANCER RESEARCH
- The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
- (2008) C. Santamaria et al. HAEMATOLOGICA
- Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy
- (2008) A S M Yong et al. LEUKEMIA
- CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
- (2008) L. G. Almeida et al. NUCLEIC ACIDS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now